Actrapid (insulin) NM Penfil solution for injections 100 IU/ml. 3 ml. cartridge №5

Description

Composition

1 ml of the drug contains:

Active substance: soluble insulin (human genetically engineered) 100 IU (3.5 mg); 1 IU corresponds to 0.035 mg anhydrous human insulin;

Excipients: zinc 7 mcg (as zinc chloride) glycerin (glycerol) 16 mg, metacresol 3.0 mg, sodium hydroxide about 2.6 mg and/or hydrochloric acid about 1.7 mg (for pH adjustment), water for injection up to 1.0 ml.

Pharmachologic effect

Actrapid® NM is a short-acting insulin preparation produced by recombinant DNA biotechnology using a strain of Saccharomyces cerevisiae. A decrease in blood glucose levels occurs due to an increase in its intracellular transport after insulin binds to insulin receptors in muscle and adipose tissue and a simultaneous decrease in the rate of glucose production by the liver. Normalization of plasma glucose concentration (up to 4.4-6.1 mmol / l) with intravenous administration of the drug Actrapid® NM in patients of the intensive care unit who underwent major surgical interventions (204 patients with diabetes mellitus and 1344 patients without diabetes mellitus) who had hyperglycemia (plasma glucose concentration> 10 mmol / l), reduced mortality by 42% (4.6% instead of 8%). The action of the drug Actrapid® NM begins within half an hour after administration, and the maximum effect is manifested within 1.5-3.5 hours, while the total duration of action is about 7-8 hours.

Indications

Diabetes. Emergency conditions in patients with diabetes mellitus, accompanied by a violation of glycemic control.

Contraindications

Hypersensitivity to human insulin or to any component that is part of this drug. Hypoglycemia.

Administration and dosage

The drug is intended for subcutaneous and intravenous administration. The dose of the drug is selected individually, taking into account the needs of the patient. The usual requirement is 0.3 to 1 IU/kg/day. The daily requirement for insulin may be higher in patients with insulin resistance (for example, during puberty, as well as in obese patients), and lower in patients with residual endogenous insulin production.

The drug is administered 30 minutes before a meal or snack containing carbohydrates.